Written answers
Thursday, 7 November 2024
Department of Health
Medicinal Products
Bríd Smith (Dublin South Central, People Before Profit Alliance)
Link to this: Individually | In context | Oireachtas source
414. To ask the Minister for Health if he will fast-track besremi reimbursement approval and call for an immediate reassessment of besremi by the NCPE given the current shortage of Pegasys; if he is aware that the NHS in England has approved besremi for interim use and that there is a clear precedent that could be followed to protect patient safety and continuity of care; his views on the case of a person (details supplied) who is desperate to secure besremi as an urgently needed treatment option; the measures they can take in the interim; and if he will make a statement on the matter. [45517/24]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines. As this is a service matter, I have asked the Health Service Executive to respond to the Deputy directly, as soon as possible.
No comments